Ca2+ entry blockers, adenosine, and neurohumors:
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Baltimore ; Munich
Urban & Schwarzenberg
1983
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XVI, 328 S. Ill. |
| ISBN: | 3541712716 0806712716 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV000222676 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 870612s1983 a||| |||| 00||| eng d | ||
| 020 | |a 3541712716 |9 3-541-71271-6 | ||
| 020 | |a 0806712716 |9 0-8067-1271-6 | ||
| 035 | |a (OCoLC)9577514 | ||
| 035 | |a (DE-599)BVBBV000222676 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a RC684.V38 | |
| 082 | 0 | |a 616.1/061 |2 19 | |
| 084 | |a VS 8108 |0 (DE-625)147711:261 |2 rvk | ||
| 100 | 1 | |a Merrill, Gary F. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Ca2+ entry blockers, adenosine, and neurohumors |c Gary F. Merrill ; Harvey R. Weiss |
| 246 | 1 | 3 | |a Ca entry blockers, adenosine, and neurohumors |
| 264 | 1 | |a Baltimore ; Munich |b Urban & Schwarzenberg |c 1983 | |
| 300 | |a XVI, 328 S. |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Adénosine - Effets physiologiques - Congrès | |
| 650 | 2 | |a Adénosine - Physiologie - Congrès comme sujet | |
| 650 | 2 | |a Agents cardiovasculaires - Congrès comme sujet | |
| 650 | 2 | |a Agents neuromédiateurs - Physiologie - Congrès comme sujet | |
| 650 | 4 | |a Calcium - Antagonistes - Essais - Congrès | |
| 650 | 4 | |a Catécholamines - Effets physiologiques - Congrès | |
| 650 | 2 | |a Inhibiteur calcique - pharmacologie - congrès | |
| 650 | 4 | |a Pharmacologie cardiovasculaire - Congrès | |
| 650 | 2 | |a Système cardiovasculaire - Physiologie - Congrès comme sujet | |
| 650 | 2 | |a Système cardiovasculaire - action des médicaments et substances chimiques - Congrès comme sujet | |
| 650 | 4 | |a Vasodilateurs - Essais - Congrès | |
| 650 | 4 | |a Adenosine |x Physiological effect | |
| 650 | 4 | |a Adenosine |x physiology |v Congresses | |
| 650 | 4 | |a Calcium Channel Blockers |x pharmacology |v Congresses | |
| 650 | 4 | |a Calcium |x Antagonists |x Testing | |
| 650 | 4 | |a Cardiovascular Agents |v Congresses | |
| 650 | 4 | |a Cardiovascular Physiology |v Congresses | |
| 650 | 4 | |a Cardiovascular System |x drug effects |v Congresses | |
| 650 | 4 | |a Cardiovascular pharmacology | |
| 650 | 4 | |a Catecholamines |x Physiological effect | |
| 650 | 4 | |a Neurotransmitter Agents |x physiology |v Congresses | |
| 650 | 4 | |a Vasodilators |x Testing | |
| 650 | 0 | 7 | |a Kreislaufmittel |0 (DE-588)4163325-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gefäßerweiterndes Mittel |0 (DE-588)4071630-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Calciumantagonist |0 (DE-588)4069807-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Catecholamine |0 (DE-588)4069876-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Wirkungsmechanismus |0 (DE-588)4292866-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Adenosin |0 (DE-588)4130804-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakodynamik |0 (DE-588)4174134-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Physiologie |0 (DE-588)4045981-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1981 |z New Brunswick NJ |2 gnd-content | |
| 689 | 0 | 0 | |a Calciumantagonist |0 (DE-588)4069807-5 |D s |
| 689 | 0 | 1 | |a Adenosin |0 (DE-588)4130804-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Calciumantagonist |0 (DE-588)4069807-5 |D s |
| 689 | 1 | 1 | |a Catecholamine |0 (DE-588)4069876-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Calciumantagonist |0 (DE-588)4069807-5 |D s |
| 689 | 2 | 1 | |a Pharmakodynamik |0 (DE-588)4174134-1 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Catecholamine |0 (DE-588)4069876-2 |D s |
| 689 | 3 | 1 | |a Physiologie |0 (DE-588)4045981-0 |D s |
| 689 | 3 | |8 1\p |5 DE-604 | |
| 689 | 4 | 0 | |a Adenosin |0 (DE-588)4130804-9 |D s |
| 689 | 4 | 1 | |a Wirkungsmechanismus |0 (DE-588)4292866-7 |D s |
| 689 | 4 | |8 2\p |5 DE-604 | |
| 689 | 5 | 0 | |a Kreislaufmittel |0 (DE-588)4163325-8 |D s |
| 689 | 5 | |8 3\p |5 DE-604 | |
| 689 | 6 | 0 | |a Gefäßerweiterndes Mittel |0 (DE-588)4071630-2 |D s |
| 689 | 6 | |8 4\p |5 DE-604 | |
| 700 | 1 | |a Weiss, Harvey R. |e Verfasser |4 aut | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000132390&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-000132390 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 4\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
Datensatz im Suchindex
| _version_ | 1804114685510811648 |
|---|---|
| adam_text | CA 2+ ENTRY BLOCKERS, ADENOSINE, AND NEUROHUMORS GARY F. MERRILL, PH.D.
GRADUATE PROGRAM IN PHYSIOLOGY RUTGERS UNIVERSITY NEW BRUNSWICK, NEW
JERSEY HARVEY R. WEISS, PH.D. DEPARTMENT OF PHYSIOLOGY AND BIOPHYSICS
UMDNJ*RUTGERS MEDICAL SCHOOL PISCATAWAY, NEW JERSEY 3* UNIVERSITATS^-
BIBLIOTHEK URBAN & SCHWARZENBERG BALTIMORE-MUNICH 1983 CONTENTS
CONTRIBUTORS IX PREFACE XV ACKNOWLEDGMENTS XVII PARTI CARDIAC ACTIONS OF
CA 2+ ENTRY BLOCKERS 1. MEASUREMENT AND BLOCK OF VOLTAGE-DEPENDENT
CALCIUM CURRENT IN THE HEART: A COMPARISON OF THE ACTIONS OF D600 AND
NISOLDIPINE 3 ROBERT S. KASS 2. ELECTROPHYSIOLOGICAL STUDIES WITH CA 2+
ENTRY BLOCKERS 19 LESLIE TUNG AND MARTIN MORAD PART II VASCULAR ACTIONS
OF CA 2+ ENTRY BLOCKERS 3. SUPPRESSED ATHEROGENESIS IN CHOLESTEROL-FED
RABBITS TREATED WITH NIFEDIPINE 39 PHILIP D. HENRY AND KAREN BENTLEY 4.
MIGHT NITRENDIPINE ENHANCE CALCIUM TRANSPORT IN VASCULAR MUSCLE? 51 7?.
KENT HERMSMEYER 5. DELINEATION OF ACTIONS OF CALCIUM ANTAGONISTS IN
VASCULAR SMOOTH MUSCLE 63 GEORGE B. WEISS V VI TABLE OF CONTENTS 6.
MECHANISMS OF STIMULATED CALCIUM INFLUX AND CONSEQUENCES OF CALCIUM
INFLUX INHIBITION 73 RODGER LOUTZENHISER AND CORNELIUS VAN BREEMEN PART
III SYSTEMIC AND MICROCIRCULATORY EFFECTS OF CA 2+ ENTRY BLOCKERS 7.
CARDIOVASCULAR EFFECTS OF CALCIUM ANTAGONISTIC DRUGS 93 STANISLAV KAZDA,
BERNWARD GARTHOFF, AND ROBERTSON TOWART 8. THE PHARMACOLOGY OF
NISOLDIPINE AND NIMODIPINE 109 BERNWARD GARTHOFF, STANISLAV KAZDA, AND
ROBERTSON TOWART 9. CONTRASTING IN VITRO AND IN VIVO VASCULAR EFFECTS OF
CALCIUM CHANNEL BLOCKERS 119 STEPHEN F. FLAIM 10. EFFECTS OF NIMODIPINE,
VERAPAMIL, AND DILTIAZEM ON BARORECEPTOR REFLEX-INDUCED BRADYCARDIA IN
DOGS 137 DAVID G. TAYLOR AND THOMAS E. KOWALSKI 11. COMPARATIVE
MICROVASCULAR ACTIONS OF CALCIUM ANTAGONISTS 155 BURTON M. ALTURA, BELLA
T. ALTURA, AND ASEFA GEBREWOLD PART IV VASCULAR ACTIONS OF ADENOSINE AND
NEUROHUMORS 12. LOCAL REGULATION OF CORONARY BLOOD FLOW IN NORMOXIA 177
ROBERT M. BERNE, STEPHEN W. ELY, ROBERT M. KNABB, ALBAN BACCHUS, AND
RAFAEL RUBIO 13. A COMPARTMENTAL MODEL OF CHANGES IN INTERSTITIAL
ADENOSINE ASSOCIATED WITH INCREASED MYOCARDIAL ADENOSINE 189 HARVEY V.
SPARKS, JOHN P. MANFREDI, AND ROBERT D. PHAIR TABLE OF CONTENTS 14.
REGULATION OF CORONARY MICROVASCULAR PERFUSION: ROLES OF ADENOSINE AND
P02 IN CAPILLARY RECRUITMENT 207 WALTER N. DURAN 15. AUTONOMIC
INFLUENCES ON CORONARY VASOMOTOR TONE AND THE TRANSMURAL DISTRIBUTION OF
MYOCARDIAL BLOOD FLOW 223 ALLYN L. MARK, U. JAMES JOHANNSEN, AND MELVIN
L. MARCUS 16. REGULATION OF CORONARY BLOOD FLOW DURING INCREASED CARDIAC
WORK 237 JACK E. MCKENZIE, ROBERT P. STEFFEN, AND FRANCIS J. HADDY 17.
MECHANISMS OF CO2-INDUCED CORONARY DILATION: DIRECT, H + OR SYMPATHETIC
ADRENERGIC 249 HARVEY R. WEISS, DIANE ELIADES, AND ERIC KORSH 18.
EFFECTS OF NOREPINEPHRINE ON CORONARY FLOW. MYOCARDIAL SUBSTRATE
UTILIZATION AND SUBCELLULAR ADENYLATES 267 ROLF BUNGER, SIBYLLE SOBOLL,
AND BERNARD PERMANETTER PARTV VASCULAR AND EXTRAVASCULAR INTERACTIONS
BETWEEN CA 2+ ENTRY BLOCKERS, ADENOSINE, AND CATECHOLAMINES 19.
ADENOSINE AND NIFEDIPINE INTERACTIONS IN THE CORONARY VASCULATURE 281
GARY F. MERRILL, MARK A. YOUNG, LARRY W. KRIEGER, SEAN G. DORRELL, AND
CAROL A. TOZZI 20. ADENOSINE RECEPTOR BINDING AND SPECIFIC RECEPTORS FOR
CALCIUM CHANNEL DRUGS 295 KENNETH M. M. MURPHY AND SOLOMON H. SNYDER 21.
CORONARY EFFECTS OF NIFEDIPINE WITH AND WITHOUT ALPHA-ADRENERGIC
STIMULATION 307 STEPHEN F. VATNER, THOMAS H. HINTZE, AND PILAR MACHO
|
| any_adam_object | 1 |
| author | Merrill, Gary F. Weiss, Harvey R. |
| author_facet | Merrill, Gary F. Weiss, Harvey R. |
| author_role | aut aut |
| author_sort | Merrill, Gary F. |
| author_variant | g f m gf gfm h r w hr hrw |
| building | Verbundindex |
| bvnumber | BV000222676 |
| callnumber-first | R - Medicine |
| callnumber-label | RC684 |
| callnumber-raw | RC684.V38 |
| callnumber-search | RC684.V38 |
| callnumber-sort | RC 3684 V38 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | VS 8108 |
| ctrlnum | (OCoLC)9577514 (DE-599)BVBBV000222676 |
| dewey-full | 616.1/061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.1/061 |
| dewey-search | 616.1/061 |
| dewey-sort | 3616.1 261 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04378nam a2200985 c 4500</leader><controlfield tag="001">BV000222676</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">870612s1983 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3541712716</subfield><subfield code="9">3-541-71271-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0806712716</subfield><subfield code="9">0-8067-1271-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)9577514</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV000222676</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC684.V38</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.1/061</subfield><subfield code="2">19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 8108</subfield><subfield code="0">(DE-625)147711:261</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Merrill, Gary F.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ca2+ entry blockers, adenosine, and neurohumors</subfield><subfield code="c">Gary F. Merrill ; Harvey R. Weiss</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Ca entry blockers, adenosine, and neurohumors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Baltimore ; Munich</subfield><subfield code="b">Urban & Schwarzenberg</subfield><subfield code="c">1983</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI, 328 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adénosine - Effets physiologiques - Congrès</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Adénosine - Physiologie - Congrès comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Agents cardiovasculaires - Congrès comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Agents neuromédiateurs - Physiologie - Congrès comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Calcium - Antagonistes - Essais - Congrès</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Catécholamines - Effets physiologiques - Congrès</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Inhibiteur calcique - pharmacologie - congrès</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacologie cardiovasculaire - Congrès</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Système cardiovasculaire - Physiologie - Congrès comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Système cardiovasculaire - action des médicaments et substances chimiques - Congrès comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vasodilateurs - Essais - Congrès</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adenosine</subfield><subfield code="x">Physiological effect</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adenosine</subfield><subfield code="x">physiology</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Calcium Channel Blockers</subfield><subfield code="x">pharmacology</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Calcium</subfield><subfield code="x">Antagonists</subfield><subfield code="x">Testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiovascular Agents</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiovascular Physiology</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiovascular System</subfield><subfield code="x">drug effects</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiovascular pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Catecholamines</subfield><subfield code="x">Physiological effect</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurotransmitter Agents</subfield><subfield code="x">physiology</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vasodilators</subfield><subfield code="x">Testing</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kreislaufmittel</subfield><subfield code="0">(DE-588)4163325-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gefäßerweiterndes Mittel</subfield><subfield code="0">(DE-588)4071630-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Calciumantagonist</subfield><subfield code="0">(DE-588)4069807-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Catecholamine</subfield><subfield code="0">(DE-588)4069876-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirkungsmechanismus</subfield><subfield code="0">(DE-588)4292866-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Adenosin</subfield><subfield code="0">(DE-588)4130804-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakodynamik</subfield><subfield code="0">(DE-588)4174134-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Physiologie</subfield><subfield code="0">(DE-588)4045981-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1981</subfield><subfield code="z">New Brunswick NJ</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Calciumantagonist</subfield><subfield code="0">(DE-588)4069807-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Adenosin</subfield><subfield code="0">(DE-588)4130804-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Calciumantagonist</subfield><subfield code="0">(DE-588)4069807-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Catecholamine</subfield><subfield code="0">(DE-588)4069876-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Calciumantagonist</subfield><subfield code="0">(DE-588)4069807-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Pharmakodynamik</subfield><subfield code="0">(DE-588)4174134-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Catecholamine</subfield><subfield code="0">(DE-588)4069876-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Physiologie</subfield><subfield code="0">(DE-588)4045981-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="4" ind2="0"><subfield code="a">Adenosin</subfield><subfield code="0">(DE-588)4130804-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2="1"><subfield code="a">Wirkungsmechanismus</subfield><subfield code="0">(DE-588)4292866-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="5" ind2="0"><subfield code="a">Kreislaufmittel</subfield><subfield code="0">(DE-588)4163325-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="5" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="6" ind2="0"><subfield code="a">Gefäßerweiterndes Mittel</subfield><subfield code="0">(DE-588)4071630-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="6" ind2=" "><subfield code="8">4\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weiss, Harvey R.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000132390&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-000132390</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">4\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1981 New Brunswick NJ gnd-content |
| genre_facet | Konferenzschrift 1981 New Brunswick NJ |
| id | DE-604.BV000222676 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T15:10:39Z |
| institution | BVB |
| isbn | 3541712716 0806712716 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-000132390 |
| oclc_num | 9577514 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XVI, 328 S. Ill. |
| publishDate | 1983 |
| publishDateSearch | 1983 |
| publishDateSort | 1983 |
| publisher | Urban & Schwarzenberg |
| record_format | marc |
| spelling | Merrill, Gary F. Verfasser aut Ca2+ entry blockers, adenosine, and neurohumors Gary F. Merrill ; Harvey R. Weiss Ca entry blockers, adenosine, and neurohumors Baltimore ; Munich Urban & Schwarzenberg 1983 XVI, 328 S. Ill. txt rdacontent n rdamedia nc rdacarrier Adénosine - Effets physiologiques - Congrès Adénosine - Physiologie - Congrès comme sujet Agents cardiovasculaires - Congrès comme sujet Agents neuromédiateurs - Physiologie - Congrès comme sujet Calcium - Antagonistes - Essais - Congrès Catécholamines - Effets physiologiques - Congrès Inhibiteur calcique - pharmacologie - congrès Pharmacologie cardiovasculaire - Congrès Système cardiovasculaire - Physiologie - Congrès comme sujet Système cardiovasculaire - action des médicaments et substances chimiques - Congrès comme sujet Vasodilateurs - Essais - Congrès Adenosine Physiological effect Adenosine physiology Congresses Calcium Channel Blockers pharmacology Congresses Calcium Antagonists Testing Cardiovascular Agents Congresses Cardiovascular Physiology Congresses Cardiovascular System drug effects Congresses Cardiovascular pharmacology Catecholamines Physiological effect Neurotransmitter Agents physiology Congresses Vasodilators Testing Kreislaufmittel (DE-588)4163325-8 gnd rswk-swf Gefäßerweiterndes Mittel (DE-588)4071630-2 gnd rswk-swf Calciumantagonist (DE-588)4069807-5 gnd rswk-swf Catecholamine (DE-588)4069876-2 gnd rswk-swf Wirkungsmechanismus (DE-588)4292866-7 gnd rswk-swf Adenosin (DE-588)4130804-9 gnd rswk-swf Pharmakodynamik (DE-588)4174134-1 gnd rswk-swf Physiologie (DE-588)4045981-0 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1981 New Brunswick NJ gnd-content Calciumantagonist (DE-588)4069807-5 s Adenosin (DE-588)4130804-9 s DE-604 Catecholamine (DE-588)4069876-2 s Pharmakodynamik (DE-588)4174134-1 s Physiologie (DE-588)4045981-0 s 1\p DE-604 Wirkungsmechanismus (DE-588)4292866-7 s 2\p DE-604 Kreislaufmittel (DE-588)4163325-8 s 3\p DE-604 Gefäßerweiterndes Mittel (DE-588)4071630-2 s 4\p DE-604 Weiss, Harvey R. Verfasser aut GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000132390&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 4\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Merrill, Gary F. Weiss, Harvey R. Ca2+ entry blockers, adenosine, and neurohumors Adénosine - Effets physiologiques - Congrès Adénosine - Physiologie - Congrès comme sujet Agents cardiovasculaires - Congrès comme sujet Agents neuromédiateurs - Physiologie - Congrès comme sujet Calcium - Antagonistes - Essais - Congrès Catécholamines - Effets physiologiques - Congrès Inhibiteur calcique - pharmacologie - congrès Pharmacologie cardiovasculaire - Congrès Système cardiovasculaire - Physiologie - Congrès comme sujet Système cardiovasculaire - action des médicaments et substances chimiques - Congrès comme sujet Vasodilateurs - Essais - Congrès Adenosine Physiological effect Adenosine physiology Congresses Calcium Channel Blockers pharmacology Congresses Calcium Antagonists Testing Cardiovascular Agents Congresses Cardiovascular Physiology Congresses Cardiovascular System drug effects Congresses Cardiovascular pharmacology Catecholamines Physiological effect Neurotransmitter Agents physiology Congresses Vasodilators Testing Kreislaufmittel (DE-588)4163325-8 gnd Gefäßerweiterndes Mittel (DE-588)4071630-2 gnd Calciumantagonist (DE-588)4069807-5 gnd Catecholamine (DE-588)4069876-2 gnd Wirkungsmechanismus (DE-588)4292866-7 gnd Adenosin (DE-588)4130804-9 gnd Pharmakodynamik (DE-588)4174134-1 gnd Physiologie (DE-588)4045981-0 gnd |
| subject_GND | (DE-588)4163325-8 (DE-588)4071630-2 (DE-588)4069807-5 (DE-588)4069876-2 (DE-588)4292866-7 (DE-588)4130804-9 (DE-588)4174134-1 (DE-588)4045981-0 (DE-588)1071861417 |
| title | Ca2+ entry blockers, adenosine, and neurohumors |
| title_alt | Ca entry blockers, adenosine, and neurohumors |
| title_auth | Ca2+ entry blockers, adenosine, and neurohumors |
| title_exact_search | Ca2+ entry blockers, adenosine, and neurohumors |
| title_full | Ca2+ entry blockers, adenosine, and neurohumors Gary F. Merrill ; Harvey R. Weiss |
| title_fullStr | Ca2+ entry blockers, adenosine, and neurohumors Gary F. Merrill ; Harvey R. Weiss |
| title_full_unstemmed | Ca2+ entry blockers, adenosine, and neurohumors Gary F. Merrill ; Harvey R. Weiss |
| title_short | Ca2+ entry blockers, adenosine, and neurohumors |
| title_sort | ca2 entry blockers adenosine and neurohumors |
| topic | Adénosine - Effets physiologiques - Congrès Adénosine - Physiologie - Congrès comme sujet Agents cardiovasculaires - Congrès comme sujet Agents neuromédiateurs - Physiologie - Congrès comme sujet Calcium - Antagonistes - Essais - Congrès Catécholamines - Effets physiologiques - Congrès Inhibiteur calcique - pharmacologie - congrès Pharmacologie cardiovasculaire - Congrès Système cardiovasculaire - Physiologie - Congrès comme sujet Système cardiovasculaire - action des médicaments et substances chimiques - Congrès comme sujet Vasodilateurs - Essais - Congrès Adenosine Physiological effect Adenosine physiology Congresses Calcium Channel Blockers pharmacology Congresses Calcium Antagonists Testing Cardiovascular Agents Congresses Cardiovascular Physiology Congresses Cardiovascular System drug effects Congresses Cardiovascular pharmacology Catecholamines Physiological effect Neurotransmitter Agents physiology Congresses Vasodilators Testing Kreislaufmittel (DE-588)4163325-8 gnd Gefäßerweiterndes Mittel (DE-588)4071630-2 gnd Calciumantagonist (DE-588)4069807-5 gnd Catecholamine (DE-588)4069876-2 gnd Wirkungsmechanismus (DE-588)4292866-7 gnd Adenosin (DE-588)4130804-9 gnd Pharmakodynamik (DE-588)4174134-1 gnd Physiologie (DE-588)4045981-0 gnd |
| topic_facet | Adénosine - Effets physiologiques - Congrès Adénosine - Physiologie - Congrès comme sujet Agents cardiovasculaires - Congrès comme sujet Agents neuromédiateurs - Physiologie - Congrès comme sujet Calcium - Antagonistes - Essais - Congrès Catécholamines - Effets physiologiques - Congrès Inhibiteur calcique - pharmacologie - congrès Pharmacologie cardiovasculaire - Congrès Système cardiovasculaire - Physiologie - Congrès comme sujet Système cardiovasculaire - action des médicaments et substances chimiques - Congrès comme sujet Vasodilateurs - Essais - Congrès Adenosine Physiological effect Adenosine physiology Congresses Calcium Channel Blockers pharmacology Congresses Calcium Antagonists Testing Cardiovascular Agents Congresses Cardiovascular Physiology Congresses Cardiovascular System drug effects Congresses Cardiovascular pharmacology Catecholamines Physiological effect Neurotransmitter Agents physiology Congresses Vasodilators Testing Kreislaufmittel Gefäßerweiterndes Mittel Calciumantagonist Catecholamine Wirkungsmechanismus Adenosin Pharmakodynamik Physiologie Konferenzschrift 1981 New Brunswick NJ |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000132390&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT merrillgaryf ca2entryblockersadenosineandneurohumors AT weissharveyr ca2entryblockersadenosineandneurohumors AT merrillgaryf caentryblockersadenosineandneurohumors AT weissharveyr caentryblockersadenosineandneurohumors |